-

04:28:21 PM

MDNA Stock News

MDNA - Medicenna Therapeutics Corp

09/30/22 7:00 AM

Nasdaq : MDNA

Medicenna Extends Period to Exercise Certain Warrants

Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (NASDAQ: MDNA TSX: MDNA), a clinical stage immunotherapy company, today announced that it has received conditional approval from the Toronto Stock Exchange to extend the expiry date

RHEA-AI

neutral

09/28/22 9:25 AM

Nasdaq : MDNA

clinical trial

Medicenna Reports Confirmed Partial Response in Pancreatic Cancer and Clinical Update on MDNA11's Monotherapy Dose Escalation Portion of the Ongoing Phase 1/2 ABILITY Study

Confirmed partial response in fourth-line metastatic pancreatic cancer patient, who had previously failed chemotherapy and checkpoint inhibitor therapy, supports MDNA11's single-agent potential in advanced solid tumors unresponsive to established treatments The observed tumor control rate of 36% in

RHEA-AI

neutral

09/22/22 7:30 AM

Nasdaq : MDNA

clinical trial

Medicenna Presents Preclinical Data Demonstrating Anti-Tumor Activity of its Anti-PD1-IL-2 BiSKIT and Long-Acting IL-4/IL-13 Super-antagonist at Cytokines 2022

IL-4/IL-13 Super-antagonist displayed monotherapy activity in multiple cancer models and in synergy with an

RHEA-AI

neutral

09/21/22 5:00 PM

Nasdaq : MDNA

Medicenna Announces Results of Annual Meeting of Shareholders

Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced the voting results from the Company's annual meeting of shareholders held today, September 21,

RHEA-AI

neutral

09/13/22 7:00 AM

Nasdaq : MDNA

Medicenna Announces Clinical Collaboration with Merck to evaluate MDNA11 in combination with KEYTRUDA(R) (pembrolizumab) in ABILITY Trial

Medicenna Therapeutics Corp. ("Medicenna" or "the

RHEA-AI

positive

09/08/22 7:30 AM

Nasdaq : MDNA

conferences

Medicenna to Present at Investor and Scientific Conferences in September

Medicenna Therapeutics Corp. ("Medicenna" or "the Company") (NASDAQ: MDNA TSX: MDNA), a clinical stage immunotherapy company, today announced that the Company management and scientific teams will present at the following investor and

RHEA-AI

neutral

08/15/22 7:00 AM

Nasdaq : MDNA

earnings

Medicenna Reports First Quarter Fiscal 2023 Financial Results and Operational Highlights

RHEA-AI

neutral

08/11/22 10:42 AM

Nasdaq : MDNA

offering

Medicenna Announces Closing of Public Offering of Units Raising US$20 Million to Advance Pipeline

Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (NASDAQ: MDNA, TSX: MDNA), a clinical stage immunotherapy company, is pleased to announce the closing of its previously announced marketed underwritten public offering of units

RHEA-AI

neutral

08/09/22 9:15 AM

Nasdaq : MDNA

offering

Medicenna Announces Pricing of US$20 Million Public Offering of Units

Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (NASDAQ: MDNA, TSX: MDNA), a clinical stage immunotherapy company, announced today that it has priced its previously-announced marketed underwritten public offering of

RHEA-AI

neutral

08/08/22 4:15 PM

Nasdaq : MDNA

offering

Medicenna Announces the Launch of a Marketed Underwritten Public Offering of Units

Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (Nasdaq: MDNA, TSX: MDNA), a clinical stage immunotherapy company, announced today the launch of a marketed underwritten public offering of units of the Company (the "Units") in the

RHEA-AI

neutral

1 2 3 4 5 6 7 8 Next

MDNA Data

IndustryPharmaceutical Preparation Manufacturing
Websitewww.medicenna.com
Security nameMedicenna Therapeutics Corp
Issue typecs
SectorManufacturing
Sic code2834
Employees2022
Tags
- Health Technology
- Biotechnology
- Manufacturing
- Biological Product (except Diagnostic) Manufacturing

About Medicenna Therapeutics Corp

Medicenna is a clinical stage immunotherapy company focused on the development of novel, highly selective versions of IL-2, IL-4 and IL-13 Superkines and first in class Empowered Superkines for the treatment of a broad range of cancers. Medicenna's long-acting IL2 Superkine asset, MDNA11, is a next-generation IL-2 with superior CD122 binding without CD25 affinity and therefore preferentially stimulates cancer killing effector T cells and NK cells when compared to competing IL-2 programs. Medicenna's lead IL4 Empowered Superkine, MDNA55, has completed a Phase 2b clinical trial for rGBM, the most common and uniformly fatal form of brain cancer. MDNA55 has been studied in five clinical trials involving 132 subjects, including 112 adults with rGBM. MDNA55 has obtained Fast-Track and Orphan Drug status from the FDA and FDA/EMA, respectively.